Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia

[1]  G. Helgason,et al.  Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia , 2021, Leukemia.

[2]  K. Ikeo,et al.  Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition , 2021, Blood advances.

[3]  C. Buske,et al.  TET3 promotes AML growth and epigenetically regulates glucose metabolism and leukemic stem cell associated pathways , 2021, Leukemia.

[4]  M. Konopleva,et al.  The Combined Treatment With the FLT3-Inhibitor AC220 and the Complex I Inhibitor IACS-010759 Synergistically Depletes Wt- and FLT3-Mutated Acute Myeloid Leukemia Cells , 2021, Frontiers in Oncology.

[5]  E. Mendez,et al.  Recurrent Human Papillomavirus–Related Head and Neck Cancer Undergoes Metabolic Reprogramming and Is Driven by Oxidative Phosphorylation , 2021, Clinical Cancer Research.

[6]  A. Regev,et al.  Cycling cancer persister cells arise from lineages with distinct programs , 2021, Nature.

[7]  Oriol Vinyals,et al.  Highly accurate protein structure prediction with AlphaFold , 2021, Nature.

[8]  Hai Yan,et al.  The implications of IDH mutations for cancer development and therapy , 2021, Nature Reviews Clinical Oncology.

[9]  P. Kuwabara,et al.  Maintenance of complex I and its supercomplexes by NDUF-11 is essential for mitochondrial structure, function and health , 2021, Journal of cell science.

[10]  J. Hirst,et al.  Cork-in-bottle mechanism of inhibitor binding to mammalian complex I , 2021, Science Advances.

[11]  S. Karthikeyan,et al.  An atlas of mitochondrial DNA genotype-phenotype associations in the UK Biobank , 2021, Nature Genetics.

[12]  M. Konopleva,et al.  IDH1/IDH2 Inhibition in Acute Myeloid Leukemia , 2021, Frontiers in Oncology.

[13]  F. Jourdan,et al.  Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia , 2021, The Journal of experimental medicine.

[14]  J. Sarry,et al.  Microenvironmental Aspartate Preserves Leukemic Cells from Therapy-Induced Metabolic Collapse. , 2020, Cell metabolism.

[15]  E. Mendez,et al.  Recurrent human papillomavirus-related head and neck cancer undergoes metabolic re-programming and is driven by oxidative phosphorylation , 2020, bioRxiv.

[16]  John G Doench,et al.  Defective NADPH production in mitochondrial disease complex I causes inflammation and cell death , 2020, Nature Communications.

[17]  E. Passegué,et al.  Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis , 2020, Nature Reviews Cancer.

[18]  S. Choe,et al.  Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. , 2020, Blood advances.

[19]  S. Weinberg,et al.  Mitochondrial ubiquinol oxidation is necessary for tumor growth , 2020, Nature.

[20]  Guowang Xu,et al.  Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism , 2020, Proceedings of the National Academy of Sciences.

[21]  H. Miyoshi,et al.  IACS-010759, a potent inhibitor of glycolysis-deficient hypoxic tumor cells, inhibits mitochondrial respiratory complex I through a unique mechanism , 2020, The Journal of Biological Chemistry.

[22]  M. V. Vander Heiden,et al.  Induction of a Timed Metabolic Collapse to Overcome Cancer Chemoresistance. , 2020, Cell metabolism.

[23]  Steven J. M. Jones,et al.  Pan-cancer analysis of whole genomes , 2020, Nature.

[24]  Qi Zhang,et al.  Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. , 2020, Blood.

[25]  Prakash Kulkarni,et al.  The Mitochondrion as an Emerging Therapeutic Target in Cancer. , 2020, Trends in molecular medicine.

[26]  S. Choe,et al.  Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. , 2019, Blood.

[27]  E. Schröck,et al.  Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin , 2019, Cancers.

[28]  A. Wei,et al.  New drugs creating new challenges in acute myeloid leukemia , 2019, Genes, chromosomes & cancer.

[29]  Huaxi Xu,et al.  Targeting citrate as a novel therapeutic strategy in cancer treatment. , 2019, Biochimica et biophysica acta. Reviews on cancer.

[30]  Xiaoying Tang,et al.  Blockade of Glutathione Metabolism in IDH1-Mutated Glioma , 2019, Molecular Cancer Therapeutics.

[31]  H. Schwalbe,et al.  Metabolic Plasticity of Acute Myeloid Leukemia , 2019, Cells.

[32]  Mike Tyers,et al.  Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of OXPHOS Dependency in Acute Myeloid Leukemia. , 2019, Cancer cell.

[33]  Michael L. Wang,et al.  Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma , 2019, Science Translational Medicine.

[34]  Won Dong Lee,et al.  Spatial-fluxomics provides a subcellular-compartmentalized view of reductive glutamine metabolism in cancer cells , 2019, Nature Communications.

[35]  J. Rabinowitz,et al.  NADPH production by the oxidative pentose-phosphate pathway supports folate metabolism , 2019, Nature Metabolism.

[36]  Jeffrey T. Chang,et al.  Abstract GS5-05: Resistance to neoadjuvant chemotherapy in triple negative breast cancer mediated by a reversible drug-tolerant state , 2019, General Session Abstracts.

[37]  D. Nomura,et al.  Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer , 2019, Science Translational Medicine.

[38]  Marni J. Falk,et al.  Landscape of Germline and Somatic Mitochondrial DNA Mutations in Pediatric Malignancies. , 2019, Cancer research.

[39]  Howard Y. Chang,et al.  Single-cell lineage tracing by endogenous mutations enriched in transposase accessible mitochondrial DNA , 2018, bioRxiv.

[40]  A. D’Alessandro,et al.  Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. , 2018, Cancer cell.

[41]  Beth Wilmot,et al.  Functional Genomic Landscape of Acute Myeloid Leukemia , 2018, Nature.

[42]  H. Alachkar,et al.  Characterization of Mutations in the Mitochondrial Encoded Electron Transport Chain Complexes in Acute Myeloid Leukemia , 2018, Scientific Reports.

[43]  M. Protopopova,et al.  An inhibitor of oxidative phosphorylation exploits cancer vulnerability , 2018, Nature Medicine.

[44]  H. V. van Laarhoven,et al.  IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[45]  R. Collins,et al.  Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML , 2018, The New England journal of medicine.

[46]  Anna L. Brown,et al.  Rare variants in Fanconi anemia genes are enriched in acute myeloid leukemia , 2018, Blood Cancer Journal.

[47]  M. V. Vander Heiden,et al.  Aspartate is an endogenous metabolic limitation for tumour growth , 2018, Nature Cell Biology.

[48]  M. Snuderl,et al.  Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumors , 2018, Nature Cell Biology.

[49]  A. Porcelli,et al.  The Oncojanus Paradigm of Respiratory Complex I , 2018, Genes.

[50]  J. Maciejewski,et al.  Wild-type and mutated IDH1/2 enzymes and therapy responses , 2018, Oncogene.

[51]  G. Dunn,et al.  Consumption of NADPH for 2-HG Synthesis Increases Pentose Phosphate Pathway Flux and Sensitizes Cells to Oxidative Stress , 2018, Cell reports.

[52]  M. McConville,et al.  Comparative Metabolomics of Mycoplasma bovis and Mycoplasma gallisepticum Reveals Fundamental Differences in Active Metabolic Pathways and Suggests Novel Gene Annotations , 2017, mSystems.

[53]  Darren L. Smith,et al.  Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist. , 2017, Cancer discovery.

[54]  Maojun Yang,et al.  Architecture of Human Mitochondrial Respiratory Megacomplex I2III2IV2 , 2017, Cell.

[55]  A. Schimmer.  Novel Mitochondrial Mechanisms of Cytarabine Resistance in Primary AML Cells. , 2017, Cancer discovery.

[56]  W. Vandertop,et al.  Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours , 2017, BMJ Open.

[57]  Marie-Liesse Asselin-Labat,et al.  Glimma: interactive graphics for gene expression analysis , 2017, bioRxiv.

[58]  V. Imbert,et al.  Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy. , 2016, Blood.

[59]  Benjamin J. Raphael,et al.  A weighted exact test for mutually exclusive mutations in cancer , 2016, Bioinform..

[60]  Navdeep S. Chandel,et al.  Fundamentals of cancer metabolism , 2016, Science Advances.

[61]  I. Mellinghoff,et al.  Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer , 2016, Clinical Cancer Research.

[62]  A. Gentles,et al.  CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia. , 2015, Cell stem cell.

[63]  U. Roessner,et al.  Quantitative profiling of polar primary metabolites of two chickpea cultivars with contrasting responses to salinity. , 2015, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[64]  M. V. Heiden,et al.  Supporting Aspartate Biosynthesis Is an Essential Function of Respiration in Proliferating Cells , 2015, Cell.

[65]  D. Sabatini,et al.  An Essential Role of the Mitochondrial Electron Transport Chain in Cell Proliferation Is to Enable Aspartate Synthesis , 2015, Cell.

[66]  E. Stein.  IDH2 inhibition in AML: Finally progress? , 2015, Best practice & research. Clinical haematology.

[67]  R. Majeti,et al.  Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia , 2015, Nature Medicine.

[68]  Yang Zhang,et al.  The I-TASSER Suite: protein structure and function prediction , 2014, Nature Methods.

[69]  Christian M. Metallo,et al.  IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism. , 2014, Cancer research.

[70]  I. Weissman,et al.  Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission , 2014, Proceedings of the National Academy of Sciences.

[71]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[72]  Fang Wang,et al.  Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation , 2013, Science.

[73]  John M. Asara,et al.  Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway , 2013, Nature.

[74]  I. Weissman,et al.  Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia , 2012, Science Translational Medicine.

[75]  Lynda Chin,et al.  Spectrum of somatic mitochondrial mutations in five cancers , 2012, Proceedings of the National Academy of Sciences.

[76]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..

[77]  Yidong Bai,et al.  Mitochondrial respiratory complex I dysfunction promotes tumorigenesis through ROS alteration and AKT activation. , 2011, Human molecular genetics.

[78]  Omar Abdel-Wahab,et al.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.

[79]  Davis J. McCarthy,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[80]  O. Shirihai,et al.  Mitochondrial fusion, fission and autophagy as a quality control axis: the bioenergetic view. , 2008, Biochimica et biophysica acta.

[81]  J. Mesirov,et al.  From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005 .

[82]  E. Shoubridge,et al.  Tissue-specific selection for different mtDNA genotypes in heteroplasmic mice , 1997, Nature Genetics.

[83]  T. Friedrich,et al.  Escherichia coli NADH dehydrogenase I, a minimal form of the mitochondrial complex I. , 1993, Biochemical Society transactions.

[84]  Otto Warburn,et al.  THE METABOLISM OF TUMORS , 1931 .

[85]  O. Warburg,et al.  THE METABOLISM OF TUMORS IN THE BODY , 1927, The Journal of general physiology.

[86]  U. Roessner,et al.  Quantification of Sugars and Organic Acids in Biological Matrices Using GC-QqQ-MS. , 2018, Methods in molecular biology.

[87]  Aaron T. L. Lun,et al.  It's DE-licious: A Recipe for Differential Expression Analyses of RNA-seq Experiments Using Quasi-Likelihood Methods in edgeR , 2016, Statistical Genomics.

[88]  A. Gentles,et al.  CD 93 Marks a Non-Quiesc ent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia Graphical , 2022 .